The InnoMedica Holding AG share (Valor: 55.897.390; ISIN: CH0558973902) is a registered share, which is electronically booked into the respective securities account of the shareholder. The InnoMedica share is a non-listed, freely tradable security. There are 15,704,685 shares outstanding (with a nominal value of CHF 0.10 each). As this is a registered share, an entry must be made in the share register so that the shareholder can exercise the voting rights of the shares. For this purpose, the holder must grant the bank an authorisation. Depending on the bank, this may be necessary each time shares are purchased.

Shares can be subscribed in a capital increase, allowing InnoMedica to realize the targeted progress of the projects. InnoMedica has carried out annual capital increases since 2013, which have expanded the shareholder base to around 1,500 shareholders and raised a total of CHF 78 million in capital. The capital increases were generally carried out in April/May. By submitting the completed subscription form and paying in the corresponding amount, the share subscription is taken into account in the allocation after completion of the capital increase. In each case, a minimum subscription set out in the capital increase applies, which must be adhered to.

Outside of the capital increases, InnoMedica offers interested buyers the opportunity to place a purchase request as part of OTC trading. If a matching is possible within the scope of the desired investment, InnoMedica will support the processing of the share purchase, in which case an expense allowance will be charged. In the case of such a purchase, the amount paid does not flow into the company.

InnoMedica offers shareholders who do not have their own bank custody account the opportunity to hold their shares directly with the company. This service has so far been provided free of charge. InnoMedica issues a confirmation of the current shareholding at the end of the year and in the event of changes to the shareholding. Shareholders are obliged to report any changes to their personal details directly.

For unlisted companies without income, the tax value is calculated on the net asset value (gross), whereby a flat-rate deduction of 30% is applied (net). This value is significantly lower than the share value, as the latter takes into account the forecast development of the company. As no revised financial statements are available as at 31 December, this is based on the net asset value of the previous year.

The main shareholders of InnoMedica are the Halbherr, Yamazaki, Früh and Bron families. Combined in a shareholder pool, they jointly control 34.9% of the company's shares.

Regardless of the company, an IPO must always be assessed in the context of the economic situation. In the biotech sector, in particular, companies with a stock market listing have recently had to show patience and have found themselves exposed to extremely unfavorable circumstances. The number of IPOs has plummeted. However, the market situation is not the only condition that must be met for an IPO. If the following conditions are also met, InnoMedica plans to go public:

• Risk profile: A stock exchange listing will substantially expand InnoMedica's shareholder base. The large number of Swiss and foreign shareholders and the participation of institutional investors place increased demands on stability, performance, and profitability. The fulfillment of these criteria is accordingly rewarded with a higher company valuation. InnoMedica believes that it will only fulfil these expectations once it has achieved increasing revenues of at least CHF 10 million per year. In addition, initial sales abroad should also have been realized, possibly supplemented by contracts with distributors or licensing agreements.
  
• Reporting: The high transparency requirements of the stock exchange are a valuable disciplinary element for corporations. InnoMedica already fulfils these requirements to a large extent with the annual documentation for the capital increase and accounting in accordance with international accounting standards.
  
• Costs: A stock market listing involves considerable administrative and financial expenditure. If possible, these expenses should be paid from initial operating income and not from the risk capital of early investors.
  
• Lead partner: A positive share price performance is central to the success of the listing project. InnoMedica negotiates with the key investors and the lead bank to create a solid financial starting position in the run-up to the listing.

InnoMedica prepares the annual report for the previous year in the first half of each year and makes it available to shareholders in electronic and physical form. As a result of the capital increases carried out annually to date, InnoMedica prepares a business plan that informs investors and interested parties about milestones already achieved and upcoming milestones. Information is also provided on the financial planning and the next steps, provided that the capital increase is fully subscribed. InnoMedica also informs shareholders about relevant milestones for achieving the company's goals via the newsletter.